0.8196

5.49% -0.0476

Ironwood Pharmaceuticals Inc (IRWD)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.8672

Offen:

$0.8728

24-Stunden-Volumen:

1.39M

Relative Volume:

0.58

Marktkapitalisierung:

$132.63M

Einnahmen:

$400.57M

Nettoeinkommen (Verlust:

$9.21M

KGV:

20.49

EPS:

0.04

Netto-Cashflow:

$146.36M

1W Leistung:

+3.64%

1M Leistung:

+12.92%

6M Leistung:

-77.91%

1J Leistung:

-87.68%

1-Tages-Spanne:

$0.8007

$0.90

1-Wochen-Bereich:

$0.7449

$0.90

52-Wochen-Spanne:

$0.5271

$7.105

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Firmenname

Ironwood Pharmaceuticals Inc

Sektor

Healthcare (1161)

Branche

Drug Manufacturers - Specialty & Generic (83)

Telefon

617-621-7722

Adresse

100 SUMMER STREET, SUITE 2300, BOSTON, MA

Mitarbeiter

253

Twitter

@ironwoodpharma

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

IRWD's Discussions on Twitter

Vergleichen Sie IRWD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IRWD Ironwood Pharmaceuticals Inc	0.8196	140.33M	400.57M	9.21M	146.36M	0.04
ZTS Zoetis Inc	152.82	68.32B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.66	46.55B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.85	43.80B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.33	19.01B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	306.41	13.79B	2.99B	1.21B	1.13B	25.06

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-15	Herabstufung	Jefferies	Buy → Hold
2025-04-15	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-04-14	Herabstufung	Citizens JMP	Mkt Outperform → Mkt Perform
2024-09-09	Eingeleitet	Leerink Partners	Market Perform
2024-08-08	Herabstufung	CapitalOne	Overweight → Equal Weight
2024-01-17	Eingeleitet	Craig Hallum	Buy
2023-12-14	Eingeleitet	Wells Fargo	Overweight
2023-11-09	Eingeleitet	Jefferies	Buy
2023-09-28	Eingeleitet	JMP Securities	Mkt Outperform
2022-09-02	Eingeleitet	CapitalOne	Overweight
2022-04-22	Eingeleitet	Piper Sandler	Overweight
2020-09-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-06-17	Eingeleitet	Northland Capital	Outperform
2019-07-10	Fortgesetzt	Credit Suisse	Neutral
2019-03-27	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-02-25	Hochstufung	H.C. Wainwright	Sell → Neutral
2019-01-24	Hochstufung	JP Morgan	Underweight → Neutral
2018-11-07	Herabstufung	Credit Suisse	Outperform → Neutral
2018-11-07	Herabstufung	JP Morgan	Neutral → Underweight
2018-07-23	Eingeleitet	H.C. Wainwright	Sell
2018-05-09	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-01-05	Herabstufung	BofA/Merrill	Buy → Underperform
2017-12-06	Herabstufung	Mizuho	Buy → Neutral
2017-07-21	Herabstufung	JP Morgan	Overweight → Neutral
2017-05-03	Eingeleitet	Wells Fargo	Outperform
2017-04-07	Bestätigt	Mizuho	Buy
2017-02-22	Bestätigt	Barclays	Equal Weight
2016-11-04	Bestätigt	Mizuho	Buy
2016-10-24	Bestätigt	Wedbush	Neutral
2016-10-10	Bestätigt	Mizuho	Buy
2016-09-27	Bestätigt	WallachBeth	Hold

Alle ansehen

Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten

Jul 24, 2025

Ironwood Pharmaceuticals Inc: Analyzing IRWD Stock Trends - investchronicle.com

Jul 24, 2025

Jul 23, 2025

What drives Ironwood Pharmaceuticals Inc. stock priceTriple-digit wealth increases - Autocar Professional

Jul 23, 2025

What analysts say about Ironwood Pharmaceuticals Inc. stockHigh-yield market plays - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Ironwood Pharmaceuticals Inc. a good long term investmentRapid portfolio appreciation - jammulinksnews.com

Jul 22, 2025

Ironwood Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com

Jul 22, 2025

Jul 17, 2025

How the Irritable Bowel Syndrome (IBS) Treatment Market Will - openPR.com

Jul 17, 2025

Jul 15, 2025

How Ironwood Pharmaceuticals Inc. stock performs during market volatilityTop Gaining Low Risk Assets - Newser

Jul 15, 2025

What makes Ironwood Pharmaceuticals Inc. stock price move sharplyFast Moving Stock Alerts - Newser

Jul 15, 2025

Why Ironwood Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Confidence Trade Setups - Newser

Jul 15, 2025

Jul 14, 2025

Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - The Globe and Mail

Jul 14, 2025

Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine - MenaFN

Jul 14, 2025

Jul 10, 2025

Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY By Investing.com - Investing.com Nigeria

Jul 10, 2025

Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY - Investing.com

Jul 10, 2025

Jul 03, 2025

Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Jul 03, 2025

Jun 30, 2025

Ironwood Pharmaceuticals, Inc.(NasdaqGS: IRWD) added to Russell 3000E Index - MarketScreener

Jun 30, 2025

Jun 25, 2025

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28% - simplywall.st

Jun 25, 2025

Jun 12, 2025

Ironwood Pharma Elects Directors at Annual Meeting - TipRanks

Jun 12, 2025

Jun 06, 2025

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? - Yahoo Finance

Jun 06, 2025

Jun 05, 2025